Hepion pharmaceuticals announces fda clearance of ind application for crv431 for covid-19

- ind expands potential indications for crv431 beyond nash to include covid-19 - - crv431 poised to move directly into phase 2 clinical study for covid-19 - - company may seek partnership(s) for covid-19 drug development - edison, nj / accesswire / december 22, 2020 / hepion pharmaceuticals, inc. (nasdaq:hepa)("hepion"), a clinical-stage biopharmaceutical company focused on artificial intelligence ("ai")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("nash") and liver disease, today announced that the u.s. food and drug administration ("fda") has accepted its investigational new drug ("ind") application for crv431, a novel cyclophilin inhibitor for the treatment of covid-19. on july 7, 2020, hepion announced a potential two-pronged strategy to treat covid-19.
HEPA Ratings Summary
HEPA Quant Ranking